Oral Ibrexafungerp Effective in Vulvovaginal Candidiasis Trial
Scynexis announced positive topline results from the phase 3 VANISH 303 trial of ibrexafungerp for the treatment of vulvovaginal candidiasis (VVC) in women.
Fungal Infections
Aspergillosis, ABPA-Related Hospitalizations in Cystic Fibrosis Confer Worse Outcomes
Nearly one-third of patients with cystic fibrosis-related hospitalizations have aspergillosis, which is associated with worse outcomes.
Oral Amphotericin B Formulation Gets Orphan Drug Status for Cryptococcosis
The Food and Drug Administration (FDA) has granted Orphan Drug designation to MAT2203 (Matinas BioPharma) for the treatment of cryptococcosis.
Novel Antifungal Gains Fast Track Designation for Seven Indications
The Food and Drug Administration (FDA) has granted Fast Track designations to both the oral and intravenous formulations of fosmanogepix (APX001; Amplyx Pharmaceuticals) for 7 antifungal indications, including treatment of: invasive candidiasis, invasive aspergillosis, scedosporiosis, fusariosis, mucormycosis, cryptococcosis and coccidioidomycosis. Fosmanogepix is a broad spectrum antifungal with a novel mechanism of action that has demonstrated…
ATS Guideline Outlines Lab Tests for Diagnosis of Fungal Infections
Guideline addresses lab testing for diagnosis of fungal infections in pulmonary medicine, critical care
Toenail Onychomycosis: Treatment Options Evaluated
A total of 26 RCTs with 8136 patients were included in this network meta analysis.
CDC: Superbug Fungus Has Sickened 600 Americans
Candida auris can survive on surfaces after routine cleaning and is often drug-resistant
New Drug Product: Tolsura
This slideshow reviews drug information for Tolsura. This slideshow reviews drug information for Tolsura.
Treatment for Cryptococcosis Gets FDA’s Orphan Drug Designation
The Food and Drug Administration (FDA) has granted Orphan Drug designation to APX001 (Amplyx Pharmaceuticals) for the treatment of cryptococcosis.
New Treatment Option for Serious Fungal Infections Now Available
Tolsura, which contains the azole antifungal itraconazole, is formulated using the Company’s proprietary SUBA (SUper-BioAvailable) technology which improves the bioavailability of poorly soluble drugs.
